Piperazine-Structured Lipid Nanoparticles Enable Enhanced Targeted Delivery of SHP-1 siRNA to Macrophages for Treatment of Atherosclerotic Vulnerable Plaques
Nano Letters · 2026
DOI: 10.1021/acs.nanolett.6c03833 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, 2026. Verfasst von Pengyu Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Low-Dimensional Materials Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontier Science Center of the Materials…. Hauptthemen laut MEDLINE: Macrophages, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Nanoparticles, Plaque, Atherosclerotic. Die Arbeit nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Atherosclerotic vulnerable plaques pose a risk for acute coronary syndrome and sudden cardiac death due to plaque rupture and thrombosis. While nanomedicines modulating macrophage functions have attracted intensive interest, efficient delivery to plaque macrophages remains challenging. Here, mannose-modified lipid nanoparticles (LNPs) are developed for targeted delivery of a novel SHP-1 (Src Homology 2 Domain-containing Phosphatase-1) siRNA to macrophages within atherosclerotic vulnerable plaques, aiming to enhance macrophage function and stabilize plaques. In ApoE–/– mice with vulnerable plaques, both MIC5 and SM-102 LNPs demonstrated robust plaque targeting capabilities (Cy5 fluorescence reaching ∼1010 p/sec/cm2/sr) and significantly reduced plaque area following SHP-1 siRNA delivery. Importantly, the piperazine-based MIC5 LNPs exhibited enhanced plaque targeting efficiency with M2 macrophage uptake efficiency reaching 46.32% as well as superior therapeutic effects. Collectively, these SHP-1 siRNA-loaded LNPs offer a promising targeted therapeutic strategy for atherosclerotic vulnerable plaques and establish a novel nanoplatform for RNA-based macrophage-modulation in various inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lab of Low-Dimensional Materials Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontier Science Center of the Materials Biology and Dynamic Chemistry, School of Materials Science and Engine…
- Vascular Surgery Division, Department of General Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai200040, China.
- School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Jiao Tong University, Shanghai200240, China.
ORCID-Profile: Hengli Zheng, Yongfeng Zhou, Dapeng Zhang, Yongsheng Li
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
- Shanghai Municipal People's Government
Zitieren
APA
Zhu, P., Huang, Y., Pan, L., Leng, Y., Zheng, H., Zhou, Y., Shi, W., Zhang, D., & Li, Y. (2026). Piperazine-Structured Lipid Nanoparticles Enable Enhanced Targeted Delivery of SHP-1 siRNA to Macrophages for Treatment of Atherosclerotic Vulnerable Plaques. Nano Letters. https://doi.org/10.1021/acs.nanolett.6c03833
Vancouver
Zhu P, Huang Y, Pan L, Leng Y, Zheng H, Zhou Y, et al. Piperazine-Structured Lipid Nanoparticles Enable Enhanced Targeted Delivery of SHP-1 siRNA to Macrophages for Treatment of Atherosclerotic Vulnerable Plaques. Nano Letters. 2026. doi:10.1021/acs.nanolett.6c03833
BibTeX
@article{Zhu2026,
author = {Zhu, Pengyu and Huang, Yijun and Pan, Liuyan and Leng, Yuheng and Zheng, Hengli and Zhou, Yongfeng and Shi, Weihao and Zhang, Dapeng and Li, Yongsheng},
title = {Piperazine-Structured Lipid Nanoparticles Enable Enhanced Targeted Delivery of SHP-1 siRNA to Macrophages for Treatment of Atherosclerotic Vulnerable Plaques},
journal = {Nano Letters},
year = {2026},
doi = {10.1021/acs.nanolett.6c03833}
}
EUVIMED